Neupogen (Filgrastim)

Filgrastim is a recombinant granulocyte colony‑stimulating factor that binds to the G‑CSF receptor on bone‑marrow progenitor cells. This binding activates signaling pathways that stimulate the proliferation, differentiation, and activation of neutrophil precursors, thereby increasing the number and function of circulating neutrophils.

The dose of Neupogen is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the patient’s clinical condition, underlying disease, and response to therapy. Dosing information is provided in the prescribing information and should not be altered without medical guidance.

Safety data for filgrastim in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties with the patient and consider alternative options when appropriate.

To order Neupogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

The primary alternative to filgrastim is pegfilgrastim, a pegylated form that has a longer half‑life and is typically given as a single dose per chemotherapy cycle. Filgrastim requires daily dosing but allows more flexible timing. Both agents belong to the G‑CSF class and have similar efficacy in reducing neutropenia, though pegfilgrastim may improve convenience for some patients.

Neupogen must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging to protect from light, and it must not be frozen or shaken. Before administration, the solution may be allowed to reach room temperature, but any unused portion should be discarded according to the product label.

Neupogen is supplied as an injectable solution for intravenous or subcutaneous injection. The route, dose, and schedule are determined by the prescribing clinician. Subcutaneous injection is most common, and the medication is typically administered once daily until the desired neutrophil count is achieved.

Serious risks include splenic rupture, acute respiratory distress syndrome (ARDS), and severe allergic reactions such as anaphylaxis. Patients should be monitored for sudden abdominal pain, respiratory difficulty, or signs of hypersensitivity, and immediate medical attention should be sought if these events occur.

Neupogen is contraindicated in patients with known hypersensitivity to filgrastim or any component of the formulation. Caution is also advised for individuals with pre‑existing splenomegaly, uncontrolled infections, or those receiving other colony‑stimulating factors, as these conditions may increase the risk of adverse events.